ALTO NEUROSCIENCE, INC. Share Price Today: Live Updates & Key Insights

ALTO NEUROSCIENCE, INC. share price today is $26.78, up -0.26%. The stock opened at $27.28 against the previous close of $26.85, with an intraday high of $27.28 and low of $26.21.

ALTO NEUROSCIENCE, INC. Share Price Chart

ALTO NEUROSCIENCE, INC.

us-stock
To Invest in {{usstockname}}
us-stock

ALTO NEUROSCIENCE, INC. Share Price Performance

$26.78 -0.0026(-0.26%) ANRO at 27 Jul 2026 01:58 PM Biotechnology
Lowest Today 26.21
Highest Today 27.28
Today’s Open 27.28
Prev. Close 26.85
52 Week High 28.85
52 Week Low 3.00
Day’s Range: Low 26.21 High 27.28
52-Week Range: Low 3.00 High 28.85
1 day return -
1 Week return +2.99
1 month return -1.03
3 month return +10.47
6 month return +64.76
1 year return +758.65
3 year return -
5 year return -
10 year return -

ALTO NEUROSCIENCE, INC. Institutional Holdings

Alpha Wave Global LP 11.61

COMMODORE CAPITAL LP 8.53

Vestal Point Capital LP 6.47

Perceptive Advisors LLC 6.30

Vanguard Group Inc 4.28

Spruce Street Capital LP 4.15

Vanguard Capital Management, LLC 3.78

Franklin Resources Inc 3.45

Vivo Capital, LLC 3.24

Vanguard Total Stock Mkt Idx Inv 3.17

Armistice Capital, LLC 2.86

Millennium Management LLC 2.57

72 Investment Holdings, LLC 2.09

iShares Russell 2000 ETF 2.09

BlackRock Inc 2.09

Franklin Biotechnology Discv A(acc)USD 2.02

Ikarian Capital, LLC 1.61

Point72 Asset Management, L.P. 1.58

Affinity Asset Advisors, LLC 1.57

Integral Health Asset Management, LLC 1.57

VR Adviser, LLC 1.57

Driehaus Capital Management LLC 1.52

Northern Trust Corp 1.48

Franklin Biotechnology Discovery A 1.15

Vanguard Institutional Extnd Mkt Idx Tr 1.09

iShares Russell 2000 Growth ETF 0.75

iShares Biotechnology ETF 0.70

State Street® SPDR® S&P® PhrmctlsETF 0.60

Biotech Growth Ord 0.52

Vanguard Russell 2000 ETF 0.47

Fidelity Extended Market Index 0.43

State St Russell Sm Cap® Idx SL Cl I 0.30

State St Russell Sm/Mid Cp® Indx SL Cl I 0.28

iShares Micro-Cap ETF 0.28

AdvisorShares Psychedelics ETF 0.22

Blackrock Extended Mkt Fund CF 0.21

Extended Equity Market Fund B 0.21

Extended Equity Market Fund E 0.21

BlackRock Extended Equity Market Fund K 0.21

NT R2000 Index Fund - NL 0.18

ALTO NEUROSCIENCE, INC. Market Status

Strong Buy: 6

Buy: 1

Hold: 1

Sell: 0

Strong Sell: 0

ALTO NEUROSCIENCE, INC. Fundamentals

Market Cap 942.27 M

PB Ratio 4.3491

PE Ratio 0.0

Enterprise Value 817.89 M

Total Assets 184.69 M

Volume 295574

ALTO NEUROSCIENCE, INC. Company Financials

Annual Revenue FY23:0 0.0M

Annual Profit FY23:null 0.0M

Annual Net worth FY23:-36305000 -36.3M

Quarterly Revenue Q1/2026:0 0.0M, Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:0 0.0M

Quarterly Profit Q1/2026:-184000 -0.2M, Q3/2025:-164000 -0.2M, Q2/2025:-100000 -0.1M, Q1/2025:-171000 -0.2M, Q3/2024:null 0.0M

Quarterly Net worth Q1/2026:-26237000 -26.2M, Q3/2025:-14181000 -14.2M, Q2/2025:-17706000 -17.7M, Q1/2025:-15169000 -15.2M, Q3/2024:-16783000 -16.8M

About ALTO NEUROSCIENCE, INC. & investment objective

Company Information Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat patients with major depressive disorder (MDD); ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor that is in Phase 2 proof-of-concept (POC) trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist, which is in Phase 2 POC trial to treat patients with MDD and higher levels of anhedonia; ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor that is in Phase 1 clinical trial for the treatment of MDD; and ALTO-208, a fixed-dose combination of pramipexole and aprepitant, an antiemetic, neurokinin-1 (NK-1) receptor antagonist for patients with Parkinson's disease for patients with Parkinson's disease. The company was incorporated in 2019 and is headquartered in Mountain View, California.

Organisation Biotechnology

Employees 68

Industry Biotechnology

CEO Dr. Amit Etkin M.D., Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

ALTO NEUROSCIENCE, INC. FAQs

What is the share price of ALTO NEUROSCIENCE, INC. today?

The current share price of ALTO NEUROSCIENCE, INC. is $26.78.

Can I buy ALTO NEUROSCIENCE, INC. shares in India?

Yes, Indian investors can buy ALTO NEUROSCIENCE, INC. shares by opening an international trading and demat account with Motilal Oswal.

How to buy ALTO NEUROSCIENCE, INC. shares in India?

You can easily invest in ALTO NEUROSCIENCE, INC. shares from India by:

Can I buy fractional shares of ALTO NEUROSCIENCE, INC.?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of ALTO NEUROSCIENCE, INC.?

ALTO NEUROSCIENCE, INC. has a market cap of $942.27 M.

In which sector does ALTO NEUROSCIENCE, INC. belong?

ALTO NEUROSCIENCE, INC. operates in the Biotechnology sector.

What documents are required to invest in ALTO NEUROSCIENCE, INC. stocks?

To invest, you typically need:

What is the PE and PB ratio of ALTO NEUROSCIENCE, INC.?

The PE ratio of ALTO NEUROSCIENCE, INC. is N/A and the PB ratio is 4.35.